Drug approvalOPENFDAApr 3
The FDA has approved a new drug made by Denali Therapeutics, but the specific name and what disease it treats are not listed in this announcement. The approval was granted on March 24, 2026. Patients and doctors should look for more details from the FDA or the company to understand what this drug does and who it might help.
WHY IT MATTERSWithout knowing the specific drug name and indication, we cannot determine the clinical significance for patients — additional information from the FDA or Denali Therapeutics is needed to assess impact.
Drug approvalOPENFDAApr 3
The FDA has approved a new drug, though the specific name and disease it treats are not listed in this announcement. The drug was developed by MAP77 and received official FDA approval on March 20, 2026. Without more details about what condition this drug treats, it's unclear how it might help patients.
WHY IT MATTERSUnable to determine specific patient impact without knowing the drug name, disease indication, or therapeutic area — this announcement lacks essential details needed to assess relevance to any particular rare disease community.
Clinical trialCLINICALTRIALSMar 26
Researchers are testing a new drug called zipalertinib to treat advanced lung cancer in patients who have a specific genetic mutation called EGFR exon 20 insertion. This mutation makes lung cancer harder to treat with standard medications. The study is looking for 220 patients to see if zipalertinib is safe and effective for this type of cancer.
WHY IT MATTERSThis trial targets EGFR exon 20 insertion mutations in advanced NSCLC, a genetic subtype that historically has limited treatment options and poor response to standard EGFR inhibitors.
ResearchCLINICALTRIALSMar 26
Researchers are studying how doctors treat a rare muscle weakness disease called generalized myasthenia gravis (gMG) in Russia. They want to understand what treatments work best in real-world practice by following 450 patients over time. This study is not testing a new drug, but rather collecting information about treatments that are already being used.
WHY IT MATTERSIf you have AChR-antibody positive generalized myasthenia gravis in Russia, this study could help doctors understand which current treatment approaches work best for patients like you in your region.
Clinical trialCLINICALTRIALSMar 26
Researchers are testing a new drug called furmonertinib in patients with advanced lung cancer that has specific genetic mutations. This is an early-stage study (Phase 1) with 160 patients to see if the drug is safe and how well it works. The drug targets uncommon mutations in EGFR and HER2 genes that some lung cancer patients have.
WHY IT MATTERSThis trial addresses treatment options for patients with advanced NSCLC carrying uncommon EGFR or HER2 mutations, which typically have fewer targeted therapy options than common mutations.
Clinical trialCLINICALTRIALSMar 26
Researchers are testing a new drug called S-606001 to see if it can help adults with late-onset Pompe disease when added to their current enzyme replacement therapy (ERT) treatment. Pompe disease is a rare genetic condition where the body can't break down a type of sugar, causing muscle weakness over time. This study will check if the new drug is safe and if it helps patients feel better or move more easily. The trial is currently looking for 45 adult participants to join.
WHY IT MATTERSThis trial is actively recruiting adults with late-onset Pompe disease who are already on enzyme replacement therapy — eligible participants may be able to access an investigational add-on treatment that could potentially improve their muscle function.
Clinical trialCLINICALTRIALSMar 26
Researchers are looking for patients with a specific type of lung cancer (non-small-cell lung cancer with EGFR PACC mutations) who have never received treatment for advanced disease. This study will test whether a new drug called firmonertinib works better and is safer than two existing drugs (osimertinib or afatinib) that doctors currently use. About 480 patients will be enrolled worldwide.
WHY IT MATTERSThis trial is actively recruiting patients with EGFR PACC mutations—a rare subset of lung cancer—and offers access to firmonertinib, a potentially more effective treatment option compared to standard first-line therapies.